Skip to main content
. 2018 May 7;20(6):594–609. doi: 10.1016/j.neo.2018.02.012

Figure 8.

Figure 8

R-Tf-D-LP4 inhibits tumor growth in a metabolically (HFD-32) induced mouse hepatocellular carcinoma (NASH-HCC) model. (A) Schematic presentation of HFD-32–induced liver cancer development and treatment schedule. Mice were randomized into two groups. One group was treated i.v. with HBSS (control), and the second was treated with the R-Tf-D-LP4 (18 mg/kg) from week 16 until week 22, when the mice were sacrificed. (B) Dissected livers from untreated and R-Tf-D-LP4–treated mice (n = 10). (C) Liver sections from untreated and R-Tf-D-LP4–treated mice stained with H&E. Blue circles indicate the tumor. (D, E) The average number of tumors per liver and the relative tumor area were measured as in Figure 3F. Results show means ±SE (n = 5, ***P ≤ .001). (F) Representative liver sections from untreated and R-Tf-D-LP4–treated mice stained with H&E showing steatosis and inflammation in peptide-untreated but not in R-Tf-D-LP4–treated mice.